A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic first wave in a German tertiary care hospital
A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic first wave in a German tertiary care hospital (Springer).
[...] Therefore, this analysis intended to examine treatment costs of COVID-19 inpatients in a German single centre during the first pandemic wave in 2020 from a healthcare payer perspective. Potential cost savings were assessed considering the administration of remdesivir according to the European Medicines Agency label.
[...]
We found that COVID-19 inpatients suffer from heterogeneous disease patterns
with a variety of incurred G-DRG tariffs and treatment costs. Theoretically
shown in the model, financial resources can be saved by the administration of
remdesivir in eligible inpatients.
[...]
Quelle: Springer, 18.08.2021
